An interventional study of Sirolimus-Ascorbic Acid Eluting Stent and Everolimus-Eluting Stent in Coronary Artery Disease, sponsored by Jung-min Ahn. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Jung-min Ahn · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 361 studies in Coronary Artery Disease with a site in Korea, Republic of — 81 open to participants now, 103 under way, 2 of them phase 3. Coronary Artery Disease · Korea, Republic of.
Among the 361 studies in Coronary Artery Disease with a site in Korea, Republic of, this one is the 42nd largest by planned enrollment of the 208 interventional ones that give a count, is one of 13 that started in 2026, is one of 91 with no phase, reaches primary completion later than 43 of the 102 other live ones, and was the 356th registered.
4,861 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →81 of the 361 studies in Coronary Artery Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Genoss Co., Ltd. · Sites in Korea, Republic of
Ages 20+
Bon-Kwon Koo · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Yonsei University · Sites in Korea, Republic of
Ages 18+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 588 Coronary Artery Disease studies recruiting now, 403 (69%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 47 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
361 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 15 · Phase 4 95
First in 2003; this study’s year is marked. 13 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,034 is above the median of 124 across 3,009 interventional studies indexed under Coronary Artery Disease.
Median enrollment 472 across the 208 interventional studies, 1,113 across the 152 observational. Of the 199 that completed or were terminated, 14 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 361 have an industry lead sponsor. The 10 most frequent:
Jung-min Ahn is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
Jung-min Ahn has 3 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
20 of the studies in Coronary Artery Disease with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02792075Seung-Jung ParkPrognosis of Coronary Stenosis Based on Intracoronary Imaging; A Multicenter, Prospective Observational Study | 2026-12 |
| NCT05340361Yonsei UniversityEfficacy and Safety of Zotarolimus-eluting Stent Overexpansion With OCT | 2026-12-31 |
| NCT05044273Jung-min AhnEvaluation of Effectiveness and Safety of Synergy XD and Synergy Megatron™ Stent | 2026-12-31 |
| NCT02038660Seung-Jung ParkDrug-Eluting Balloon Registry in Routine Clinical Practice | 2026-12-31 |
| NCT06066450Genoss Co., Ltd.Efficacy of OSFIT Drug-Eluting Stent in Coronary Ostial Artery Stenosis | 2026-12-31 |
Add all 20 to your calendar (.ics) → With an account.
Among the 361 studies in Coronary Artery Disease with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to demonstrate the primary hypothesis that, in patients with chronic and acute coronary syndromes requiring percutaneous coronary intervention (PCI), the novel sirolimus-ascorbic acid eluting stent (D+Storm Novonix) is non-inferior to the standard treatment, the everolimus-eluting stent (Synergy XD), with respect to the incidence of target lesion failure (TLF) at 1 year after treatment, where TLF is defined as a composite of cardiovascular death, target vessel myocardial infarction, and clinically driven target-lesion revascularization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Women who are pregnant, breastfeeding, or of who meet any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
D+STORM NOVONIX stent
Device: Sirolimus-Ascorbic Acid Eluting Stent
SYNERGY XD
Device: Everolimus-Eluting Stent
bioabsorbable polymer Sirolimus-Ascorbic Acid Eluting Stent
bioabsorbable polymer everolimus-eluting stent
The event rate of Target Lesion Failure
Target Lesion Failure is defined as a composite of cardiovascular death, target vessel myocardial infarction, and clinically driven target-lesion revascularization.
Time frame: 1 year
The event rate of Device success
Acute Success Endpoints\_lesion level
Time frame: 1 year
The event rate of Procedural success
Acute Success Endpoints\_patient level
Time frame: 1 year
The event rate of Death from any causes
Major Composite Clinical Endpoints\_Patient-Oriented Clinical Endpoint, POCE
Time frame: 1 year
The event rate of Any stroke
Major Composite Clinical Endpoints\_Patient-Oriented Clinical Endpoint, POCE
Time frame: 1 year
The event rate of Any myocardial infarction
Major Composite Clinical Endpoints\_Patient-Oriented Clinical Endpoint, POCE
Time frame: 1 year
The event rate of Any repeat revascularization
Major Composite Clinical Endpoints\_Patient-Oriented Clinical Endpoint, POCE
Time frame: 1 year
The event rate of Cardiovascular death
Major Composite Clinical Endpoints\_Target Vessel Failure
Time frame: 1 year
The event rate of Target vessel myocardial infarction
Major Composite Clinical Endpoints\_Target Vessel Failure
Time frame: 1 year
The event rate of Target vessel revascularization
Major Composite Clinical Endpoints\_Target Vessel Failure
Time frame: 1 year
The event rate of All-cause death
Individual Clinical Endpoints\_Mortality
Time frame: 1 year
The event rate of Cardiac death
Individual Clinical Endpoints\_Mortality
Time frame: 1 year
The event rate of Non-cardiac death
Individual Clinical Endpoints\_Mortality
Time frame: 1 year
The event rate of All myocardial infarction including Q wave and Non-Q wave
Individual Clinical Endpoints\_Myocardial Infarction
Time frame: 1 year
The event rate of Non-target vessel myocardial infarction
Individual Clinical Endpoints\_Myocardial Infarction
Time frame: 1 year
The event rate of All revascularization
Individual Clinical Endpoints\_Revascularization
Time frame: 1 year
The event rate of All target lesion revascularization
Individual Clinical Endpoints\_Revascularization
Time frame: 1 year
The event rate of All target vessel revascularization
Individual Clinical Endpoints\_Revascularization
Time frame: 1 year
The event rate of Non-target vessel revascularization
Individual Clinical Endpoints\_Revascularization
Time frame: 1 year
The event rate of Any stroke
Individual Clinical Endpoints\_Stroke
Time frame: 1 year
The event rate of Ischemic stroke
Individual Clinical Endpoints\_Stroke
Time frame: 1 year
The event rate of Hemorrhagic stroke
Individual Clinical Endpoints\_Stroke
Time frame: 1 year
The event rate of Definite or probable stent thrombosis
Safety Endpoints
Time frame: 1 year
The event rate of Definite stent thrombosis
Safety Endpoints
Time frame: 1 year
The event rate of Probable stent thrombosis
Safety Endpoints
Time frame: 1 year
The event rate of The Bleeding Academic Research Consortium (BARC) type 2, 3, 4, 5
Safety Endpoints
Time frame: 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Jun 2027, 8 months after the start.
Of 753 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 8 months is below that.
Counting every sponsor, half of 930 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jung-min Ahn